1. Home
  2. Products
  3. Customized ADCs
  4. TNFRSF10B
  5. Anti-TNFRSF10B (Conatumumab)-MC-MMAF ADC

Anti-TNFRSF10B (Conatumumab)-MC-MMAF ADC (CAT#: ADC-W-1864)

This ADC product is comprised of an anti-TNFRSF10B monoclonal antibody conjugated via a MC linker to MMAF. The MMAF is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAF binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.

  • ADC Target
  • ADC Antibody
  • ADC Linker
  • ADC payload drug
  • Name
  • TNFRSF10B
  • Alternative Names
  • TNFRSF10B; tumor necrosis factor receptor superfamily, member 10b; tumor necrosis factor receptor superfamily member 10B; CD262; DR5; KILLER; TRAIL R2; TRICK2A; TRICKB; Fas-like protein; death receptor 5; cytotoxic TRAIL receptor-2; apoptosis inducing receptor TRAIL-R2; apoptosis inducing protein TRICK2A/2B; TNF-related apoptosis-inducing ligand receptor 2; death domain containing receptor for TRAIL/Apo-2L; tumor necrosis factor receptor-like protein ZTNFR9; p53-regulated DNA damage-inducible cell death receptor(killer); TRICK2; ZTNFR9; TRAILR2; TRICK2B; TRAIL-R2; KILLER/DR5;
  • Target Entrez Gene ID
  • 8795
  • Overview
  • The protein encoded by this gene is a member of the TNF-receptor superfamily, and contains an intracellular death domain. This receptor can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL/APO-2L), and transduces an apoptosis signal. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by this protein. Two transcript variants encoding different isoforms and one non-coding transcript have been found for this gene.
  • Overview
  • Human Anti-TNFRSF10B IgG1-kappa antibody, Conatumumab
  • Generic name
  • Conatumumab
  • Host animal
  • Human
  • Name
  • MC (maleimidocaproyl)
  • Description
  • Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.
  • Name
  • MMAF
  • Description
  • Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.

For Research Use Only. NOT FOR CLINICAL USE.

Related Products

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

CAMouse™-Fully Human Antibody Generation Platform
Reviews
Development of Monoclonal Antibodies
Literature
CAMouse™-Fully Human Antibody Generation Platform
Protocol

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-W-1864. Click the button above to contact us or submit your feedback about this product.

Quick Links

ADC Toxins
Drug-linker Complexes
Customized ADCs
Anti-Ab ADCs

Other Products

Same Target Same Linker Same Payload
CAT# Product Name Linker Payload
ADC-W-1871 Anti-TNFRSF10B (Drozitumab)-MC-Vc-PAB-MMAE ADC MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) MMAE
ADC-W-1873 Anti-TNFRSF10B (Drozitumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC MC-Vc-PAB-DMEA-(PEG2) duocarmycin SA
ADC-W-1875 Anti-TNFRSF10B (Lexatumumab)-SPDB-DM4 ADC SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine)
ADC-W-1877 Anti-TNFRSF10B (Lexatumumab)-MC-Vc-PAB-MMAE ADC MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) MMAE
ADC-W-1880 Anti-TNFRSF10B (Tigatuzumab)-SMCC-DM1 ADC SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
CAT# Product Name Linker Payload
ADC-W-478 Anti-ENPP3-Mc-MMAF ADC Mc (maleimidocaproyl) MMAF (Monomethyl auristatin F)
ADC-W-2612 Anti-MS4A1 (Rituximab)-MC-MMAF ADC MC (maleimidocaproyl) MMAF
ADC-W-485 Anti-EphA2 (clone 1C1)-Mc-MMAF ADC Mc (maleimidocaproyl) MMAF (Monomethyl auristatin F)
ADC-W-517 Anti-TM4SF1 ( clone v1.10)-Mc-LP2 ADC Mc (maleimidocaproyl) LP2 (chemical name mc-3377)
ADC-W-2622 Anti-NCAM1 (Lorvotuzumab )-MC-MMAF ADC MC (maleimidocaproyl) MMAF
CAT# Product Name Linker Payload
ADC-W-2591 Anti-EGFR (Cetuximab)-MC-MMAF ADC MC (maleimidocaproyl) MMAF
ADC-W-2600 Anti-GPNMB (Glembatumumab)-MC-MMAF ADC MC (maleimidocaproyl) MMAF
ADC-W-2556 Anti-CD79B (Polatuzumab )-MC-MMAF ADC MC (maleimidocaproyl) MMAF
ADC-AA-063 Anti-HIgG(Fab)-N-MMAF ADC Noncleavable linkers MMAF
ADC-W-2622 Anti-NCAM1 (Lorvotuzumab )-MC-MMAF ADC MC (maleimidocaproyl) MMAF

Online Inquiry

Name:
*Phone:
*E-mail Address:
*Products or Services Interested:
Company/Institution
Project Description:

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.